# Noninferiority of one HPV vaccine dose to two doses (ESCUDDO)

Source: https://onco.cc/key-papers/paper-kreimer-escuddo-one-dose-hpv-nejm-2025/  
OnCo record `paper-kreimer-escuddo-one-dose-hpv-nejm-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In a trial of 20,330 girls aged 12 to 16 in Costa Rica, one dose of either the bivalent or the nonavalent HPV vaccine protected against HPV 16 and 18 infection as well as two doses.

## Summary

ESCUDDO randomised girls aged 12 to 16, in a 1:1:1:1 ratio, to one or two doses of a bivalent or a nonavalent HPV vaccine. The primary end point was new HPV 16 or 18 infection from month 12 to month 60 persisting for at least 6 months, with a noninferiority margin of 1.25 infections per 100 participants. Vaccine effectiveness was estimated against 3,005 unvaccinated girls and women in a parallel survey. The trial was funded by the US National Cancer Institute and others; ClinicalTrials.gov lists its site at ACIB in Liberia, Guanacaste.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: New England Journal of Medicine
- Year: 2025
- DOI: 10.1056/NEJMoa2506765
- Authors: Kreimer AR, Porras C, Liu D, Hildesheim A, et al.
- Findings: 20,330 participants were randomised and 3,005 unvaccinated participants enrolled in the survey.; Rate difference between one and two doses: -0.13 infections per 100 participants for the bivalent vaccine (95% CI -0.45 to 0.15) and 0.21 for the nonavalent vaccine (95% CI -0.09 to 0.51); both noninferior (P<0.001).; Vaccine effectiveness was at least 97% in each of the four groups.; No safety concerns were identified.
- What it means: One dose of HPV vaccine protected girls against infection with HPV 16 and 18, the two types that cause most cervical cancers, as well as two doses did, so the same supply of vaccine could protect more girls.
- Caveats: The end point is persistent infection, not precancer or cancer.; The primary end point counts infections from month 12 to month 60 after vaccination.

## Sources

- DOI: https://doi.org/10.1056/NEJMoa2506765
- PubMed: https://pubmed.ncbi.nlm.nih.gov/41337735/
- ClinicalTrials.gov NCT03180034: https://clinicaltrials.gov/study/NCT03180034

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [HPV bivalent vaccine (types 16 and 18)](https://onco.cc/drugs/hpv-bivalent-vaccine/), [Nonavalent HPV vaccine](https://onco.cc/drugs/gardasil-9/)
- institutions: [Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN)](https://onco.cc/institutions/acib-funin-costa-rica/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)

---
JSON: https://onco.cc/api/v1/entities/paper-kreimer-escuddo-one-dose-hpv-nejm-2025.json